Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1969 1
1979 4
1980 1
1981 1
1983 1
1984 3
1985 11
1986 11
1987 7
1988 7
1989 6
1990 6
1991 7
1992 4
1993 10
1994 8
1995 7
1996 3
1997 6
1998 10
1999 10
2000 13
2001 9
2002 16
2003 19
2004 28
2005 35
2006 36
2007 32
2008 33
2009 28
2010 43
2011 32
2012 43
2013 32
2014 49
2015 32
2016 32
2017 52
2018 35
2019 45
2020 58
2021 69
2022 58
2023 57
2024 53
2025 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

993 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Among authors: lin sm. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Clinical Trial.
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Shen YC, et al. Among authors: lin sm. J Clin Oncol. 2024 Dec;42(34):4060-4070. doi: 10.1200/JCO.24.00645. Epub 2024 Aug 28. J Clin Oncol. 2024. PMID: 39197119 Free PMC article.
Optimization applications of Goldbach's conjecture.
Lin BMT, Lin SM, Shyu SJ. Lin BMT, et al. Among authors: lin sm. Heliyon. 2023 Oct 5;9(10):e20550. doi: 10.1016/j.heliyon.2023.e20550. eCollection 2023 Oct. Heliyon. 2023. PMID: 37867794 Free PMC article.
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.
Shao YY, Wang SY, Lin SM; Diagnosis Group,; Systemic Therapy Group. Shao YY, et al. Among authors: lin sm. J Formos Med Assoc. 2021 Apr;120(4):1051-1060. doi: 10.1016/j.jfma.2020.10.031. Epub 2020 Nov 14. J Formos Med Assoc. 2021. PMID: 33199101 Free article.
What is mzXML good for?
Lin SM, Zhu L, Winter AQ, Sasinowski M, Kibbe WA. Lin SM, et al. Expert Rev Proteomics. 2005 Dec;2(6):839-45. doi: 10.1586/14789450.2.6.839. Expert Rev Proteomics. 2005. PMID: 16307524 Review.
993 results